Pityriasis rubra pilaris (type I) following administration of the BNT162b2 mRNA COVID ‐19 vaccine: Successful treatment with ustekinumab and acitretin

Le résumé fourni par la source

Pityriasis rubra pilaris (type I) following administration of the BNT162b2 mRNA COVID-19 vaccine: Successful treatment with ustekinumab and acitretin Dear Editor, Pityriasis rubra pilaris (PRP) is a rare erythematous papulosquamous disorder, clinically and pathologically similar to psoriasis. 1 Since the approval of the mRNA vaccines for SARS-CoV-2, multiple cutaneous adverse events were associated with the administration of the vaccine.2,3 We report a case of recalcitrant PRP following administration of the BNT162b2 COVID-19 vaccine (Pfizer-BioNTech).A 47-year-old Caucasian man presented us with fast development of scaly reddish plaques on scalp, back, chest, and limbs that appeared 15 days after he received the booster with the BNT162b2 vaccine in October 2021 (Figure 1A).He was vaccinated with two doses of CoronaVac (Sinovac Biotech) in March 2021, without intercurrences.He did not have any evidence of previous comorbidities or active infection and was not using other drugs.The patient also reported no personal or family history of psoriasis, PRP, or other autoimmune disease.Laboratory investigations showed a raised C-reactive-protein level and liver and kidney function altered.Serological testing for

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.